SKYE BIOSCIENCE, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.04 USD | -8.53% |
|
-15.90% | +302.57% |
| Apr. 23 | Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Transportation Index | CI |
| Apr. 12 | Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Composite Index | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 14.8 | 33.59 | 338.7 | - | - |
| Enterprise Value (EV) 1 | 14.8 | 33.59 | 338.7 | 338.7 | 338.7 |
| P/E ratio | -0.41 x | -0.51 x | -15.4 x | -13.8 x | -11.6 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | -14.2 x | -9.76 x | -8.3 x |
| FCF Yield | - | - | -7.05% | -10.2% | -12.1% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 3,654 | 12,349 | 28,063 | - | - |
| Reference price 2 | 4.050 | 2.720 | 12.07 | 12.07 | 12.07 |
| Announcement Date | 3/31/23 | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -34.74 | -25.27 | -35.76 | -40.75 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -37.64 | -23.26 | -34.09 | -39.57 |
| Net income 1 | -19.48 | -37.64 | -23.26 | -34.09 | -39.57 |
| Net margin | - | - | - | - | - |
| EPS 2 | -10.00 | -5.370 | -0.7850 | -0.8750 | -1.040 |
| Free Cash Flow 1 | - | - | -23.89 | -34.72 | -40.83 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/31/23 | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | -4.086 | -5 | -6 | -6.5 | -7.5 | -8.5 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -4.42 | -4.5 | -5.55 | -6.1 | -7.15 | -8.2 |
| Net income 1 | -24.95 | -4.42 | -4.5 | -5.55 | -6.1 | -7.15 | -8.2 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -3.170 | - | -0.1600 | -0.1400 | -0.1600 | -0.1800 | -0.2100 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 11/14/23 | 3/22/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -23.9 | -34.7 | -40.8 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | 1.16 | 1.5 | 1.79 |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 3/31/23 | 3/22/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
12.07
USD
Average target price
22.5
USD
Spread / Average Target
+86.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +302.57% | 339M | |
| +18.34% | 47.02B | |
| +48.77% | 41.86B | |
| +0.61% | 41.76B | |
| -4.27% | 28.8B | |
| +11.71% | 26.05B | |
| -21.82% | 19.15B | |
| +3.72% | 12.55B | |
| +28.22% | 12.34B | |
| -4.49% | 11.82B |
- Stock Market
- Equities
- EMBI Stock
- Financials Skye Bioscience, Inc.